Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0JHXJI
ADC Name
WO2017089895A1 ADC68
Synonyms
WO2017089895A1 ADC68
   Click to Show/Hide
Organization
LegoChem Biosciences, Inc.
Drug Status
Investigative
Indication
In total 1 Indication(s)
Burkitt lymphoma [ICD11:2A85]
Investigative
Drug-to-Antibody Ratio
2
Structure
Antibody Name
Anti-CD19 mAb DI-B4
  Antibody Info 
Antigen Name
B-lymphocyte antigen CD19 (CD19)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
WO2017089895A1_ADC68 linker
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.04
nM
Ramos cells
Burkitt lymphoma
Half Maximal Inhibitory Concentration (IC50) 
0.05
nM
Ramos cells
Burkitt lymphoma
Half Maximal Inhibitory Concentration (IC50) 
0.09
nM
Ramos cells
Burkitt lymphoma
Half Maximal Inhibitory Concentration (IC50) 
> 33.3
nM
K562 cells
Chronic myeloid leukemia
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.04 nM Positive CD19 expression (CD19+++/++)
Method Description
ADCs wereincubated in human plasma for 5 seconds (0h), followed by SRB invitro cytotoxicity test using Ramos cells for 72hr.
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.05 nM Positive CD19 expression (CD19+++/++)
Method Description
ADCs wereincubated in human plasma for 168 hours (168h), followed by SRB invitro cytotoxicity test using Ramos cells for 72hr.
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.09 nM Positive CD19 expression (CD19+++/++)
Method Description
Ramos cells were seeded in a 96-wellplate at 20,000 cells/well in 100 uL of growth media. The cells were incubated at 37°C in5% CO, for 1 day. Serial dilutions of ADCs from 33.33 nM to 5.1 pM in 100 uL media were added to the wells, and the cells were incubated with the antibody & ADCs for 72 hours.
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 33.30 nM Negative CD19 expression (CD19-)
Method Description
K562 cells were seeded in a 96-wellplate at 20,000 cells/well in 100 uL of growth media. The cells were incubated at 37°C in5% CO, for 1 day. Serial dilutions of ADCs from 33.33 nM to 5.1 pM in 100 uL media were added to the wells, and the cells were incubated with the antibody & ADCs for 72 hours.
In Vitro Model Chronic myeloid leukemia K562 cells CVCL_0004
References
Ref 1 Antibody-drug conjugates comprising branched linkers and methods related thereto; 2017-06-01.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.